This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CVS Health (CVS) Retail Business Grows Despite Cost Pressure
by Zacks Equity Research
CVS Health's (CVS) retail business sees solid rebound in front-store sales with strength across all categories.
SmileDirectClub (SDC) to Boost Europe Presence, Enter France
by Zacks Equity Research
SmileDirectClub (SDC) since its foray into Europe in 2019 has been seeing remarkable market penetration of its oral care products.
Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.
Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.
Boston Scientific's (BSX) New Buyout to Aid Clot Management
by Zacks Equity Research
The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.
NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout
by Zacks Equity Research
NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.
Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months
by Zacks Equity Research
The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).
Stryker's (SYK) Trauma & Extremities Arm Unveils New Product
by Zacks Equity Research
The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given a strong second-quarter performance and strength in the Structural Heart business.
Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge
by Zacks Equity Research
Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.
ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy
by Zacks Equity Research
A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients
Smith+Nephew (SNN) Releases New Features for Hip Arthroplasty
by Zacks Equity Research
Smith+Nephew (SNN) introduced the RI.HIP NAVIGATION software on the CORI Surgical System and announced the commercial availability of RI.INSIGHTS at the AAOS 2021 Annual Meeting.
Earnings Estimates Moving Higher for VAREX IMAGING (VREX): Time to Buy?
by Zacks Equity Research
VAREX IMAGING (VREX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Strong recovery across businesses and strength in plasma franchise benefited Haemonetics (HAE) during the first quarter of fiscal 2022.
Zimmer Biomet's (ZBH) Data Favors mymobility with Apple Watch
by Zacks Equity Research
Zimmer Biomet (ZBH) presented four data presentations backing the mymobility with Apple Watch platform at the AAOS 2021 Annual Meeting.
The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories
4 MedTechs to Gain in 2H21 Beating the Delta Variant-Led Dip
by Urmimala Biswas
Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.
Cardiovascular Systems (CSII) Introduces Diamondback in Canada
by Zacks Equity Research
The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.
Medtronic (MDT) Receives FDA Nod for Evolut FX TAVR System
by Zacks Equity Research
Medtronic's (MDT) Evolut FX TAVR system offers hemodynamic and durability benefits of the Evolut platform with new product and procedure enhancements.
Zimmer Biomet (ZBH) Receives FDA Nod for ROSA Hip System
by Zacks Equity Research
The recent FDA go-ahead for Zimmer Biomet's (ZBH) ROSA Hip System will aid surgeons perform robotically-assisted direct anterior total hip replacement surgery.
Hill-Rom (HRC) PSS Growth Solid Despite Tough Y/Y Comparison
by Zacks Equity Research
Hill-Rom's (HRC) recent launches, including the Helion Integrated Surgical System in the United States, buoy optimism.
Abbott (ABT) Receives FDA Nod for Amplatzer Amulet Device
by Zacks Equity Research
The FDA's go-ahead for Abbott's (ABT) Amulet will offer a unique treatment option in the United States that seals off the left atrial appendage entirely without any blood-thinning drugs.
Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance across the Life Science and Clinical Diagnostics businesses drove the top line for Bio-Rad (BIO).
Quest Diagnostics (DGX), eMed Deal to Boost BinaxNOW Sales
by Zacks Equity Research
Under the collaboration, eMed's Certified Guide will supervise Quest Diagnostics' (DGX) BinaxNOW home testing process virtually.